2021 •
Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
Authors: Rick Oerlemans, Angel Jonathan Ruiz-Moreno, Yingying Cong, Nilima Dinesh Kumar, Marco A. Velasco-Velazquez, Constantinos G. Neochoritis, Jolanda Smith, Fulvio Reggiori, Matthew R. Groves, Alexander Dömling
Venue: RSC Medicinal Chemistry
Type: Article
Abstract: α-Ketoamide HCV protease inhibitors covalently bind to SARS-CoV-2 3CLpro. Boceprevir is a particular promising repurposed drug as it potently inhibits cellular viral proliferation.
Popularity: This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the
underlying citation network.
Influence: This indicator reflects the overall/total impact of an article in the research community at large, based on the
underlying citation network (diachronically).
Citation Count: This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in
the research community at large, based on the underlying citation network (diachronically).
Impulse: This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation
network.
We have placed cookies on your device to help make this website and the services we offer better. By using this site, you agree to the use of cookies. Learn more